A Struggling Hospira, Inc. (HSP) Moves the Pieces on Its Manufacturing Chessboard
4/18/2013 8:06:30 AM
For more than a year, Hospira has made headlines thanks to a spate of ongoing, serious and systemic manufacturing problems that have led to numerous FDA inspections and warning letters. The situation has grown so worrisome that some speculate a consent decree is likely. In hopes of making the intractable somehow manageable, the drugmaker last year hired John Elliott, who had run Cherokee Pharmaceuticals and spent more than a quarter of a century overseeing operations at GlaxoSmithKline (GSK). At the time, he was described as "a seasoned global leader" with loads of manufacturing experience and "specific expertise in injectable pharmaceuticals"
comments powered by